山西中医药大学学报2025，Vol.26Issue(3)：276-281,6.DOI:10.19763/j.cnki.2096-7403.2025.03.08
清肝排毒饮联合恩替卡韦治疗慢性乙型肝炎的疗效及免疫机制研究
Efficacy and immunological mechanisms of Qinggan Paidu Yin combined with entecavir in treating chronic hepatitis B
摘要
Abstract
Objective:To observe the effect of Qinggan Paidu Yin combined with entecavir in patients with chronic hepatitis B(CHB)and explore its immunological mechanisms.Methods:A total of 108 inpatients and outpatients with CHB in the Department of Infectious Diseases of the School of Medicine of Anhui University of Chinese Medicine were se-lected as research subjects.According to two different treatment methods,they were randomly divided into a treatment group(n=54)and a control group(n=54).Patients in the treatment group received oral administration of Qinggan Paidu Yin and entecavir,while patients in the control group took entecavir only.Patients in both groups were treated continuously for 12 weeks.The clinical efficacy,liver function,liver fibrosis indicators,IFN-γ,PD-1 level and adverse reactions were com-pared and analyzed between the two groups before treatment and 12 weeks after treatment.Results:After 12 weeks of treat-ment:① The total effective rate of the treatment group,in which Qinggan Paidu Yin was combined,was significantly higher than that of the control group with entecavir alone(P<0.05);② In terms of liver function,the levels of alanine ami-notransferase(ALT),aspartate aminotransferase(AST)and total bilirubin(TBIL)were significantly lower than those before treatment,and those in the treatment group were lower than those in the control group(P<0.05);③ The levels of type IV collagen(IV-C),hyaluronic acid(HA),laminin(LN)and type III procollagen N-terminal peptide(PC-III)were signifi-cantly lower than those before treatment,and those in the treatment group were lower than those in the control group(P<0.05,P<0.01);④ The level of IFN-γ was significantly higher than that before treatment,and that in the combined treat-ment group was higher than that in the control group(P<0.05);⑤ The level of molecular protein PD-1 was significantly lower than that before treatment,and that in the treatment group was lower than that in the control group(P<0.05);⑥ Com-parison of adverse reactions between the two groups showed no statistically significant difference.Conclusion:The combi-nation of Qinggan Paidu Yin and entecavir can improve the overall efficacy in patients with CHB,alleviate liver function and fibrosis,which is more effective than entecavir alone.关键词
慢性乙型肝炎/清肝排毒饮/恩替卡韦/免疫机制Key words
CHB/Qinggan Paidu Yin/entecavir/immunological mechanisms分类
医药卫生引用本文复制引用
史甜甜,刘丽丽,蒋伟峰..清肝排毒饮联合恩替卡韦治疗慢性乙型肝炎的疗效及免疫机制研究[J].山西中医药大学学报,2025,26(3):276-281,6.基金项目
国家中医药管理局全国名老中医药专家传承工作室建设项目(国中医药人教函[2022]175号) （国中医药人教函[2022]175号）
安徽省高校自然科学研究重点项目(KJ2021A0567) （KJ2021A0567）
安徽省卫生健康杰出人才项目(皖卫函[2023]392号) （皖卫函[2023]392号）
